| 35385-4 |
CV2 Ab.IgG |
Titr |
CSF |
Pt |
SemiQn |
|
|
ACTIVE |
CV2 IgG Ab [Titer] in Cerebral spinal fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
35385-4 |
|
|
|
|
Both |
|
|
|
0 |
CV2 IgG Titr CSF |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Collapsin response mediator protein 5; Collapsin response mediator protein 5 Ab; Collapsin response mediator protein 5 Ab.IgG; CRMP5; CRMP-5; Dilution factor; Dilution Factor (Titer); Immune globulin G; Immunoglobulin G; Neuro; Neurology; Point in time; POP66; Random; Serology; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr; ULIP |
2.75 |
2.13 |
|
|
|
|
|
|
|
{titer} |
|
|
Collapsin response mediator protein 5 (CRMP5) Ab is also known as CV2 Ab. Changed component from Collapsin response mediator protein 5 Ab.IgG to harmonize with existing terms. |
0 |
| 35386-2 |
CV2 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
CV2 IgG Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
35386-2 |
|
|
|
|
Both |
|
|
|
0 |
CV2 IgG Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Collapsin response mediator protein 5; Collapsin response mediator protein 5 Ab; Collapsin response mediator protein 5 Ab.IgG; CRMP5; CRMP-5; Dilution factor; Dilution Factor (Titer); Immune globulin G; Immunoglobulin G; Point in time; POP66; Random; Serology; Serum; SmQn; SR; Titer; Titered; Titre; Ttr; ULIP |
2.75 |
2.13 |
|
|
|
|
|
|
|
{titer} |
|
|
Collapsin response mediator protein 5 (CRMP5) Ab is also known as CV2 Ab. Changed component from Collapsin response mediator protein 5 Ab.IgG to harmonize with existing terms. |
0 |
| 35387-0 |
Cholesterol.in lipoprotein (little a) |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Cholesterol. in Lipoprotein (a) [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
35387-0 |
|
|
|
|
Both |
|
|
|
0 |
Lpa Cholest SerPl Ql |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Lip; Lipid; Lipoprot; Lipoproteins; LP; Lp(a); LP(a) Cholesterol; LPa; Lpa Cholest; Lpa Cholesterol; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35388-8 |
Cholesterol.in lipoprotein (little a) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cholesterol. in Lipoprotein (a) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/mL;mg/dL |
|
|
|
|
|
|
CHEM |
|
35388-8 |
|
|
|
|
Both |
|
|
|
0 |
Lpa Cholest SerPl-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Heart Disease; Level; Lip; Lipid; Lipoprot; Lipoproteins; LP; Lp(a); LP(a) Cholesterol; LPa; Lpa Cholest; Lpa Cholesterol; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.13 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 35389-6 |
Cholesterol.in chylomicrons |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Cholesterol.in chylomicrons [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
Detected;Not detected |
|
|
|
|
|
CHEM |
|
35389-6 |
|
|
|
|
Both |
|
|
|
0 |
Cholest in Chylo SerPl Ql |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholest in Chylo; Cholesterol total; Cholesterols; Chylomicron; Heart Disease; Lipid; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; ULDL; Ultra low density lipoproteins |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 3539-4 |
Dextromethorphan |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Dextromethorphan [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
3539-4 |
|
|
|
|
Both |
|
|
|
0 |
D-methorphan Ur Ql |
|
|
|
|
|
Dextro-methorphan; D-methorphan; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35390-4 |
Vaccinia virus DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Vaccinia virus DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35390-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VACV DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; VACV |
2.69 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35391-2 |
Taenia solium larva Ab.IgG |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Taenia solium larva IgG Ab [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
OD units |
|
|
|
|
|
|
MICRO |
|
35391-2 |
|
|
|
|
Both |
|
|
|
0 |
T sol lar IgG CSF-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Cysticercosis; Cysticercus; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; T sol; T sol lar; T solium; Tapeworm |
2.73 |
2.13 |
|
|
|
|
|
|
|
{OD_unit} |
|
|
|
0 |
| 35392-0 |
Hantavirus Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Hantavirus IgG Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
Index Value |
|
|
|
|
|
|
MICRO |
|
35392-0 |
|
|
|
|
Both |
|
|
|
0 |
Hantavirus IgG Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hanta virus; Hemorrhagic fever with renal syndrome; HFRS; HPS; HTNV; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Orthohantavirus; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SNV; SR |
2.73 |
2.13 |
|
|
|
|
|
|
|
{Index_val} |
|
|
|
0 |
| 35393-8 |
Hantavirus Ab.IgM |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Hantavirus IgM Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
Index Value |
|
|
|
|
|
|
MICRO |
|
35393-8 |
|
|
|
|
Both |
|
|
|
0 |
Hantavirus IgM Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Hanta virus; Hemorrhagic fever with renal syndrome; HFRS; HPS; HTNV; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Orthohantavirus; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SNV; SR |
2.73 |
2.13 |
|
|
|
|
|
|
|
{Index_val} |
|
|
|
0 |
| 35394-6 |
Legionella pneumophila 1 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Legionella pneumophila 1 IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35394-6 |
|
|
|
|
Both |
|
|
|
0 |
L pneumo1 IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; i; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L pneumo; L pneumo1; L pneumonphila; Legion; Legionela; Legionella pneumophila serogroup 1; Microbiology; Ordinal; Philadelphia 1; Pneu; pneum; Pneumophilia; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35395-3 |
Legionella pneumophila 1 Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Legionella pneumophila 1 IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35395-3 |
|
|
|
|
Both |
|
|
|
0 |
L pneumo1 IgM Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; i; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L pneumo; L pneumo1; L pneumonphila; Legion; Legionela; Legionella pneumophila serogroup 1; Microbiology; Ordinal; Philadelphia 1; Pneu; pneum; Pneumophilia; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35396-1 |
Enterovirus RNA |
PrThr |
Tiss |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Enterovirus RNA [Presence] in Tissue by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35396-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
EV RNA Tiss Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Entero virus; EV; EV-PCR; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; Tissue; Tissue, unspecified; TMA; Transcription mediated amplification |
2.63 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35397-9 |
Epstein Barr virus DNA |
PrThr |
Bone mar |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Epstein Barr virus DNA [Presence] in Bone marrow by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35397-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
EBV DNA Mar Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; BM; BON; Bone marrow; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; EBV; Epstn; HHV-4; human herpesvirus 4; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; MAR; Marrow (bone); Microbiology; minimal angle of resolution; Minimum angle of resolution; Mono; Mononucleosis; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35398-7 |
Epstein Barr virus DNA |
PrThr |
Mouth |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Epstein Barr virus DNA [Presence] in Mouth by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35398-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
EBV DNA Mouth Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; EBV; Epstn; HHV-4; human herpesvirus 4; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Mono; Mononucleosis; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Oral; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35399-5 |
Varicella zoster virus DNA |
PrThr |
Eye |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Varicella zoster virus DNA [Presence] in Eye by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35399-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VZV DNA Eye Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Chicken pox; Chicken pox virus; Chickenpox; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Eyeball; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Occular; Oculis; Ophthalmologic; Optic globe; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Shingles; Strand Displacement Amplification; TMA; Transcription mediated amplification; Vision; Visual; VZ; VZV; Zoster |
2.63 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 354-1 |
Neomycin |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Neomycin [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
354-1 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Neomycin Islt MLC |
|
|
|
Y |
|
Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Neosporin; Point in time; QNT; Quan; Quant; Quantitative; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 3540-2 |
Dextromoramide |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Dextromoramide [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
3540-2 |
|
|
|
|
Both |
|
|
|
0 |
D-moramide Ur Ql |
|
|
|
|
|
Dextrodiphenopyrine; Dextro-moramide; D-moramid; D-moramide; DRUG/TOXICOLOGY; Drugs; Jetrium; Narcolo; Ordinal; Palfium; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35400-1 |
Varicella zoster virus DNA |
PrThr |
Tiss |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Varicella zoster virus DNA [Presence] in Tissue by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35400-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
VZV DNA Tiss Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Chicken pox; Chicken pox virus; Chickenpox; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpes zoster; HHV-3; Human herpesvirus 3; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Shingles; Strand Displacement Amplification; Tissue; Tissue, unspecified; TMA; Transcription mediated amplification; VZ; VZV; Zoster |
2.73 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35401-9 |
Cytomegalovirus DNA |
PrThr |
Bronchial |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Cytomegalovirus DNA [Presence] in Bronchial specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35401-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CMV DNA Bronch Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Bro; CMV; Cytomegalo virus; Cytomgal; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HHV-5; Human Herpesvirus-5; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lung; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QL; Qual; Qualitative; Random; Respiratory; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35402-7 |
Leishmania donovani Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Leishmania donovani IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35402-7 |
|
|
|
|
Both |
|
|
|
0 |
L donovani IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L donovani; Leishmaniasis; Leishmaniosis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35403-5 |
Leishmania donovani Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Leishmania donovani IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35403-5 |
|
|
|
|
Both |
|
|
|
0 |
L donovani IgM Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L donovani; Leishmaniasis; Leishmaniosis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35404-3 |
Leishmania braziliensis Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Leishmania brasilensis IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35404-3 |
|
|
|
|
Both |
|
|
|
0 |
L braziliensis IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L brasilensis; L brasiliensis; L braziliensis; Leishmaniasis; Leishmaniosis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35405-0 |
Leishmania braziliensis Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Leishmania brasilensis IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35405-0 |
|
|
|
|
Both |
|
|
|
0 |
L braziliensis IgM Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; L brasilensis; L brasiliensis; L braziliensis; Leishmaniasis; Leishmaniosis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 35406-8 |
Leishmania mexicana Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Leishmania mexicana IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
35406-8 |
|
|
|
|
Both |
|
|
|
0 |
L mexicana IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; L mexicana; Leishmaniasis; Leishmaniosis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.13 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
